Forward-Looking StatementsThis press release contains "forward-looking" statements, including all statements regarding the future conduct of the European clinical study and the continued development and planned features of, regulatory filings related to and approval and commercial launch of products in Cardica's proposed MicroCutter product line, including the timing thereof. Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "planned," "designed," "should," "may," "subject to," "will," "plan," "expect" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including that Cardica's European clinical study may not be completed on schedule, or at all; Cardica may not be successful in its efforts to complete the development and obtain regulatory approval of, and commercially launch, the Cardica MicroCutter product line on Cardica's anticipated timeframe; that Cardica's current and any future products may never gain any significant degree of market acceptance; that the planned MicroCutter products face development, regulatory, reimbursement and manufacturing risks; that Cardica's intellectual property rights may not provide adequate protection; that Cardica's sales, marketing and distribution strategy and capabilities may not be sufficient or successful; that Cardica requires substantial additional capital; and that general business and economic conditions may impair Cardica's ability to market and develop products. These and other risks are detailed under the heading "Risk Factors" and elsewhere in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2011. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
Cardica Enrolls First Patients In European MicroCutter™ Clinical Study
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.